Hints and tips:
...Simon Lowth, who took over as interim chief executive after the abrupt departure of David Brennan last spring and was another frontrunner to run the company permanently, retains his post as chief financial...
...He takes over from Simon Lowth, AstraZeneca’s chief financial officer, who was named interim chief executive after the board ousted David Brennan in May....
...We have not ousted David Brennan. He has decided to retire.”...
...Tony Zook, global commercial vice-president, has also been cited as a possible replacement, although he comes from a similar marketing background to Mr Brennan....
...Unstoppable: Finding Hidden Assets to Renew the Core and Fuel Profitable Growth By Chris Zook Harvard Business School Press £17.99, 208 pages FT bookshop price: £14.39 Bain & Co’s leading strategist completes...
...“Abraxane brings significant benefits to cancer patients over existing therapies and complements and extends our U.S. oncology product portfolio,” said Tony Zook, chief executive of AstraZeneca U.S....
International Edition